Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...
More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major U.S ...
In the diet-medication sweepstakes, we have a winner. While all five drugs approved by the Food & Drug Administration for weight loss best a placebo in helping patients lose weight, a drug known ...
Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...
These findings further confirm the safety profile of Saxenda and are comparable to the safety data seen at 56 weeks. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a ...
PARSIPPANY, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S.
The GLP-1 receptor agonist, which was first approved for adults in December 2014, is now a treatment option for adolescents with obesity ages 12-17 as adjunct to diet and exercise. More specifically, ...
As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...
Share on Pinterest Experts say people should expect to be on weight loss medications for a long period of time. NurPhoto/Getty Images Researchers report that more than half of people on weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback